Cinacalcet is an effective treatment for secondary hyperparathyroidism in patients on dialysis. Until now, no randomized, placebo-controlled, long-term trial has tested this drug in individuals ...

Cinacalcet (Sensipar ® /Mimpara ®, Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is ...

Calcimimetic drugs such as cinacalcet (Sensipar ® /Mimpara ®, Amgen Inc., Thousand Oaks, CA) suppress secretion of parathyroid hormone by sensitizing calcium receptors to extracellular ionized ...

In light of this trend, Dr. Reddy's launched its own brand of cinacalcet tablets. It noted in a press release that the Sensipar brand of cinacalcet, made by Amgen Inc., made $312 million in sales ...